An­a­lysts track a pay­er re­volt against Sarep­ta’s con­tro­ver­sial Duchenne drug

When the FDA’s Janet Wood­cock pushed through a con­tro­ver­sial ap­proval for Sarep­ta’s Ex­ondys 51 for Duchenne mus­cu­lar dy­s­tro­phy in Sep­tem­ber, she cre­at­ed a test case for pay­ers who were es­sen­tial­ly be­ing asked to re­im­burse for an ex­per­i­men­tal drug.

But in­stead of rolling with the sit­u­a­tion and pay­ing a price that starts at $300,000 or so a year, many of the pay­ers are kick­ing back hard, ac­cord­ing to a sur­vey of pay­ers con­duct­ed by Jef­feries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.